Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca’s Imfinzi and Tremelimumab with Chemotherapy Demonstrated Overall Survival Benefit in Trial for Non-Small Cell Lung Cancer

americanpharmaceuticalreviewMay 08, 2021

Tag: AstraZeneca , Imfinzi , tremelimumab , POSEIDON , NSCLC

PharmaSources Customer Service